Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

被引：0
|
作者：
Grommes, C. [1 ]
Gavrilovic, I. [1 ]
Kaley, T. [1 ]
Nolan, C. [1 ]
Omuro, A. [1 ]
Wolfe, J. [1 ]
Pentsova, E. [1 ]
Hatzoglou, V. [1 ]
Mellinghoff, I. K. [1 ]
Deangelis, L. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Neurol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw367.9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
331PD
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma
    Grommes, Christian
    Pastore, Alessandro
    Gavrilovic, Igor
    Kaley, Thomas
    Nolan, Craig
    Omuro, Antonio M.
    Wolfe, Julia
    Pentsova, Elena
    Hatzoglou, Vaois
    Mellinghoff, Ingo
    DeAngelis, Lisa
    BLOOD, 2016, 128 (22)
  • [22] First Results of the Acse Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort
    Hoang-Xuan, Khe
    Houot, Roch
    Soussain, Carole
    Blonski, Marie
    Schmitt, Anna
    Delwail, Vincent
    Damaj, Gandhi Laurent
    Ghesquieres, Herve
    Peyrade, Frederic
    Tempescul, Adrian
    Abraham, Julie
    Agape, Philippe
    Ahle, Guido
    Baize, Nathalie
    Bories, Pierre
    Campello, Chantal
    Gyan, Emmanuel
    Jardin, Fabrice
    Rey, Philippe
    Choquet, Sylvain
    Houillier, Caroline
    Cassoux, Nathalie
    Touitou, Valerie
    Martin-Duverneuil, Nadine
    Legrand, Frederic
    Lamrani-Ghaouti, Assia
    Querel, Ophelie
    Labouret, Natalie Hoog
    Simon, Clotilde
    Chevret, Sylvie
    Massard, Christophe
    BLOOD, 2020, 136
  • [23] Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma
    O'Brien, P
    Roos, D
    Pratt, G
    Liew, K
    Barton, M
    Poulsen, M
    Olver, I
    Trotter, G
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 519 - 526
  • [24] Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma
    Korfel, Agnieszka
    Schlegel, Uwe
    Herrlinger, Ulrich
    Dreyling, Martin
    Schmidt, Christian
    von Baumgarten, Luisa
    Pezzutto, Antonio
    Grobosch, Thomas
    Kebir, Sied
    Thiel, Eckhard
    Martus, Peter
    Kiewe, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1757 - +
  • [25] Phase II trial of temsirolimus for relapsed/refractory primary central nervous system lymphoma (PCNSL)
    Kiewe, P.
    Martus, P.
    Thiel, E.
    Grobosch, T.
    Schlegel, U.
    Herlinger, U.
    Dreyling, M.
    Schmidt, C.
    Korfel, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 268 - 268
  • [26] A Phase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
    Ramchandren, Radhakrishnan
    Phillips, Tycel J.
    Devata, Sumana
    Gabali, Ali M.
    Houde, Christiane
    Pregja, Silva
    Aghamohammadi, Golbon
    Wesson, Emily
    Hutto, Tony
    Fanale, Michelle A.
    BLOOD, 2017, 130
  • [27] Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma
    Grommes, Christian
    Tang, Sarah S.
    Wolfe, Julia
    Kaley, Thomas J.
    Daras, Mariza
    Pentsova, Elena I.
    Piotrowski, Anna F.
    Stone, Jacqueline
    Lin, Andrew
    Nolan, Craig P.
    Manne, Malbora
    Codega, Paolo
    Campos, Carl
    Viale, Agnes
    Thomas, Alissa A.
    Berger, Michael F.
    Hatzoglou, Vaios
    Reiner, Anne S.
    Panageas, Katherine S.
    DeAngelis, Lisa M.
    Mellinghoff, Ingo K.
    BLOOD, 2019, 133 (05) : 436 - 445
  • [28] Phase 1B of ibrutinib and high-dose methotrexate for recurrent/refractory CNS lymphoma.
    Grommes, Christian
    Stone, Jacqueline
    Nolan, Craig
    Tsyvkin, Elina
    Wolfe, Julia
    Mellinghoff, Ingo K.
    DeAngelis, Lisa Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
    Bartlett, Nancy L.
    Costello, Brian A.
    LaPlant, Betsy R.
    Ansell, Stephen M.
    Kuruvilla, John G.
    Reeder, Craig B.
    Thye, Lim S.
    Anderson, Daniel M.
    Krysiak, Kilannin
    Ramirez, Cody
    Qi, Jing
    Siegel, Barry A.
    Griffith, Malachi
    Griffith, Obi L.
    Gomez, Felicia
    Fehniger, Todd A.
    BLOOD, 2018, 131 (02) : 182 - 190
  • [30] A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404
    Cohen, Jonathon B.
    Portell, Craig A.
    Hamadani, Mehdi
    Jegede, Opeyemi
    Diefenbach, Catherine
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Kahl, Brad S.
    BLOOD, 2019, 134
12345